Abstract
Tuberculosis (TB) is the second leading infectious cause of mortality worldwide with about two million deaths per year. The only licensed TB vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG) shows limited protection efficacy suggesting an improved vaccination strategy is required. Recently, several TB vaccine candidates have entered clinical trials. These vaccine candidates are live mycobacterial vaccines designed to replace BCG or subunit vaccines designed to boost immunity induced by BCG. Vaccines with different strategy such as therapeutic vaccines, which can also be used in combination with drug therapy, are in the early stages of development to resolve latent TB or reactivation from the latent state. In this review, we discuss about development of BCG and BCG-based vaccines and further studies necessary for novel TB vaccine development to sterilize tuberculosis.
| Original language | English |
|---|---|
| Pages (from-to) | 236-243 |
| Number of pages | 8 |
| Journal | Journal of Bacteriology and Virology |
| Volume | 44 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2014 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Microbiology
- Immunology
- Virology
Cite this
}
Mycobacterium bovis Bacillus Calmette-Guerin (BCG) and BCG-based vaccines against tuberculosis. / Cha, Seung Bin; Shin, Sung Jae.
In: Journal of Bacteriology and Virology, Vol. 44, No. 3, 01.01.2014, p. 236-243.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Mycobacterium bovis Bacillus Calmette-Guerin (BCG) and BCG-based vaccines against tuberculosis
AU - Cha, Seung Bin
AU - Shin, Sung Jae
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Tuberculosis (TB) is the second leading infectious cause of mortality worldwide with about two million deaths per year. The only licensed TB vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG) shows limited protection efficacy suggesting an improved vaccination strategy is required. Recently, several TB vaccine candidates have entered clinical trials. These vaccine candidates are live mycobacterial vaccines designed to replace BCG or subunit vaccines designed to boost immunity induced by BCG. Vaccines with different strategy such as therapeutic vaccines, which can also be used in combination with drug therapy, are in the early stages of development to resolve latent TB or reactivation from the latent state. In this review, we discuss about development of BCG and BCG-based vaccines and further studies necessary for novel TB vaccine development to sterilize tuberculosis.
AB - Tuberculosis (TB) is the second leading infectious cause of mortality worldwide with about two million deaths per year. The only licensed TB vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG) shows limited protection efficacy suggesting an improved vaccination strategy is required. Recently, several TB vaccine candidates have entered clinical trials. These vaccine candidates are live mycobacterial vaccines designed to replace BCG or subunit vaccines designed to boost immunity induced by BCG. Vaccines with different strategy such as therapeutic vaccines, which can also be used in combination with drug therapy, are in the early stages of development to resolve latent TB or reactivation from the latent state. In this review, we discuss about development of BCG and BCG-based vaccines and further studies necessary for novel TB vaccine development to sterilize tuberculosis.
UR - http://www.scopus.com/inward/record.url?scp=84907858328&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907858328&partnerID=8YFLogxK
U2 - 10.4167/jbv.2014.44.3.236
DO - 10.4167/jbv.2014.44.3.236
M3 - Review article
AN - SCOPUS:84907858328
VL - 44
SP - 236
EP - 243
JO - Journal of Bacteriology and Virology
JF - Journal of Bacteriology and Virology
SN - 1598-2467
IS - 3
ER -